Abstract Details

Title A Standardized 40 Hz Vibrotactile Stimulation Platform for Alzheimer’s Disease

Topic Aging, Dementia, and Behavioral Neurology

Presentation(s) P10 - Poster Session 10 (8:00 AM-9:00 AM)

Poster/Presentation
Number 12-012

Objective To develop a reproducible 40 Hz vibrotactile stimulation (VTS) platform for in vitro models of Alzheimer’s disease (AD), benchmark its effects across neuronal, vascular, and immune systems, and assess its potential for medical device development.

Background Gamma-frequency stimulation has shown therapeutic promise in AD, but translation requires standardized delivery methods with validated cellular effects. Vibrotactile approaches offer a safe, noninvasive route that could be developed into a clinically deployable medical device.

Design/Methods A sinusoidal 40 Hz waveform was amplified to drive a vibration actuator (8.6 Ω, ≤1 W). Output voltage stability was verified using an oscilloscope. The platform was applied to: (1) SH-SY5Y neurons exposed to Aβ for analysis of viability, autophagy, and tau phosphorylation; (2) primary human pericytes exposed to Aβ for intracellular Ca²? measurement using Fura-2; and (3) BV2 microglia treated with LPS for cytokine profiling, morphology, and stress-kinase signaling.

Results The device delivered stable 40 Hz stimulation within defined safety parameters. Biological effects included improved neuronal survival, enhanced autophagy, and reduced tau hyperphosphorylation; normalization of Aβ-induced Ca²? overload in pericytes; and suppression of LPS-induced cytokine expression and JNK activation in microglia.

Conclusions

This standardized VTS platform demonstrates reproducible cross-cellular benefits relevant to AD pathology. Its scalability and safety profile support further development as a medical device for noninvasive neuromodulation in AD. A clinical trial is planned to evaluate feasibility, safety, and cognitive outcomes, positioning vibroacoustic gamma stimulation as a novel therapeutic strategy in dementia care.

Authors/Disclosures
Tanya Xi, MD, PhD, MBA (AriBio) PRESENTER	Dr. Xi has received personal compensation for serving as an employee of AriBio Co., Ltd.. Dr. Xi has received personal compensation for serving as an employee of McKinsey & Company. Dr. Xi has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for McKinsey & Company.
Chang-Ho Shin, Business Director	Mr. Shin has nothing to disclose.
Byung-Woo M. Kang	Mr. Kang has nothing to disclose.
Min-Woo CHO	Mr. CHO has nothing to disclose.
Jae-Young y. Ha, MSc	Mr. Ha has received personal compensation for serving as an employee of AriBio Co. Ltd. Mr. Ha has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for AriBio Co. Ltd.. Mr. Ha has stock in AriBio Co. Ltd.. Mr. Ha has stock in Solux Ltd.. An immediate family member of Mr. Ha has stock in AriBio Co. Ltd.. The institution of Mr. Ha has received research support from Ministry of Health and Welfair, Republic of Korea.
Jai Jun J. Choung	Dr. Choung has nothing to disclose.
Dong-Keun Song, MD, PhD	Dr. Song has nothing to disclose.
Hee-Kyoung Ko, PhD	Dr. Ko has nothing to disclose.
Fred Kim	Mr. Kim has received personal compensation for serving as an employee of AriBio Co., Ltd.. An immediate family member of Mr. Kim has stock in AriBio Co., Ltd.. The institution of an immediate family member of Mr. Kim has received research support from National Research Council of Science & Technology (NST) through the Aging Convergence Research Center. Mr. Kim has received intellectual property interests from a discovery or technology relating to health care.
Vitella Fomenko	Miss Fomenko has received personal compensation for serving as an employee of AriBio Co., Ltd.. Miss Fomenko has received personal compensation for serving as an employee of Cognito Therapeutics Inc..
Hee-Kyoung Ko, PhD	Dr. Ko has nothing to disclose.

��ɫ��

��ɫ��